The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration

Bibliographic Details
Main Authors:	Zineh Issam, Woodcock Janet
Format:	Article
Language:	English
Published:	BMC 2010-04-01
Series:	Human Genomics
Online Access:	http://www.humgenomics.com/content/4/4/221

Similar Items

Quantitative Systems Pharmacology: A Regulatory Perspective on Translation
by: Issam Zineh
Published: (2019-06-01)

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs
by: Robert N. Schuck, et al.
Published: (2019-05-01)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
by: Nadia Zuabi, et al.
Published: (2016-11-01)

Role of patient advocacy stakeholders in science-based regulatory policy at the U.S. Food and Drug Administration (FDA)
Published: ()

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
by: Fei Liang, et al.
Published: (2020-08-01)

Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels
by: Wang, Bo
Published: (2016)

US food and drug administration Indian site inspections: An experience
by: Pooja Mahajan, et al.
Published: (2012-01-01)

Vaccines, Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food and Drug Administration
by: Kathryn C. Zoon
Published: (1999-08-01)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
by: Joe Lex
Published: (2016-11-01)

Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations
by: Yassine Kamal Lyauk, et al.
Published: (2019-09-01)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.
by: Helen W Sullivan, et al.
Published: (2016-01-01)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.
by: Robert K M Choy, et al.
Published: (2020-07-01)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
by: Carrie M. Kuehn
Published: (2019-08-01)

Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.
by: Stanton A Glantz, et al.
Published: (2009-07-01)

Barriers to Sustainable Food Trade: China’s Exports Food Rejected by the U.S. Food and Drug Administration 2011–2017
by: Xiaowei Wen, et al.
Published: (2018-05-01)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
by: Amira Osman, et al.
Published: (2018-04-01)

The practice of climate change scientists in the UK and US : money, scientists and climate change
by: Matthews, Anna Zosia
Published: (2004)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
by: Jingjing Yu, et al.
Published: (2020-07-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
by: Fleisher B, et al.
Published: (2017-12-01)

The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases.
by: Michael J Brennan
Published: (2009-07-01)

Patterns of Regularity Noncompliance Identified by the U.S. Food and Drug Administration and Their Effects on Meta-analyses
by: Garmendia, Craig A
Published: (2018)

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
by: Kakadia S, et al.
Published: (2018-10-01)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
by: Joshua D. Wallach, et al.
Published: (2019-06-01)

Hermeneutics of Food and Drug Regulatory Policy
by: Joseph A. Tuminello, III
Published: (2020-12-01)

Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration Animal rule
by: Chia-Wei eTsai, et al.
Published: (2015-12-01)

Bilateral implantation of +3.0 D multifocal toric intraocular lenses: results of a US Food and Drug Administration clinical trial
by: Lehmann R, et al.
Published: (2017-07-01)

Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration
by: Mathangi Gopalakrishnan, et al.
Published: (2021-03-01)

The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
by: Timothy C Guetterman, et al.
Published: (2017-10-01)

Scientists' warning on endangered food webs
by: R. H. Heleno, et al.
Published: (2020-04-01)

Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
by: Erik De Clercq
Published: (2019-02-01)

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
by: Lexchin, J.
Published: (2021)

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint
by: Brian E. Lacy, et al.
Published: (2018-05-01)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
by: Di Maria Jiang, et al.
Published: (2019-04-01)

Social Scientists and Public Administration in the Lula Silva Government
by: Maria Celina D’Araujo, et al.
Published: (2009-06-01)

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
by: Erick H Turner, et al.
Published: (2012-01-01)

A protocol for topographic-guided corneal repair utilizing the US Food and Drug Administration-approved Wavelight Contoura
by: Motwani M
Published: (2017-03-01)

Scientists work with industry to safeguard food and water
by: W.R. Gomes
Published: (1997-03-01)

Daina Kārkliņa (1950–2020) Food Scientist
by: Ciproviča Inga
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_obvqko7k75589h2ate6to9sgar